Bionure project of the GAEM's Accelerator Programme raises more than €1M via equity crowdfunding

Valued at 9,400,000€ and with an estimated ROI of 1400%, Bionure is now at 110% of its funding goal and keeps on rising. The capital raised from over 240 investors sharing 9.27% equity in the business will be used by the company to to complete their preclinical phase and begin the BN201 promising phase-I clinical trials. They will test its effectiveness in patients with Acute Optic Neuritis (AON), a condition known to be one of the first signs of multiple sclerosis.

“Capital Cell has been a constant support helping to raise awareness of our campaign. The platform is a great way to expand funding possibilities, reaching investors that we would had never been able to reach”, say Albert G. Zamora, Bionure CEO.

Bionure’s campaign ‘#estamosaesto’ (‘we are this close’) is capturing the interest of an heterogeneous ‘crowd’ of investors. “We have been contacted by multiple sclerosis patients, by their relatives and friends, who see this an exceptional opportunity to help. Whilst on the other hand, there’s the impressive business opportunity that Bionure represents: the estimated market for a neuro regenerative drug such as BN201 is about €1.2 billion. That’s why we are capturing the interest of big investors who see the high social impact but also the high profitability of their investment”, reveals Daniel Oliver CEO of Capital Cell.

The first drug with neuroprotective and remyelinating activity

Multiple sclerosis is a neurodegenerative disease in which the immune system destroys the nervous system, degrading the myelin layer that covers and protects the nerves. BN201 is the first molecule of its kind that prevents axonal damage and promotes the survival of neuronal cells, which would effects of neuroprotection, recover the cell population and promote remyelination of these cells, and thus, could stop some effects of multiple sclerosis.

This new drug acts as a neuroprotector, preventing the nervous system from damage and reversing the detrimental effects. At present, there is no other drug with this dual role of neuroprotection and regeneration, making BN201 a unique product and a hope to multiple sclerosis patients, but also other neurodegenerative diseases such as Parkinson and Alzheimer.

• More information to invest in the campaign: http://capitalcell.net/investment/bionure64/